Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon alpha lozenge · 1 trial · 4 indications
Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT \& pulmonary function. The same radiologist did the comparsion for all subjects.
| Name | Type | Description |
|---|---|---|
| Interferon alpha oral lozenge | DRUG | dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year |
Inclusion Criteria: * The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement. 1. Exclusion of other known causes of interstitial...